Acute Respiratory Distress Syndrome News and Research

RSS

Breakthrough approaches enhance RNA delivery while minimizing inflammation

Lipid nanoparticles (LNPs) are tiny fat bubbles that are used to deliver medicines, genes, and RNA into cells. However, in some cases LNPs can cause harmful inflammation as a result of the process of RNA delivery.

11 Aug 2025

AI reshapes ARDS care by predicting risk, guiding ventilation, and personalizing treatment

Artificial intelligence and machine learning are transforming acute respiratory distress syndrome (ARDS) management, enabling earlier detection, precision risk stratification, and tailored therapies. Emerging AI techniques promise to improve outcomes, but real-world clinical validation and integration remain critical challenges.

21 Jul 2025

Integrating phytomedicine and nanotechnology in managing COVID-19 related heart disease

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology.

22 May 2025

New RNA-based blood test offers insight into cancer and tissue damage

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments and tissue injury caused by non-cancerous conditions.

21 Apr 2025

Study reveals key cause of ventilator-induced lung injury

A new study from Tulane University suggests that repeated collapse and reopening of tiny alveoli-air sacs in the lungs essential for breathing-during mechanical ventilation may cause microscopic tissue damage, playing a key role in ventilator-related injuries that contribute to thousands of deaths annually.

3 Mar 2025

Antibody therapy provides protection against severe H5N1 avian flu in monkeys

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of Pittsburgh and NIH Vaccine Research Center researchers report today in Science.

30 Jan 2025

Ozone therapy shows promise in treating sepsis-induced lung injury

Sepsis, a severe and often fatal complication of infection, is a leading cause of both ALI and acute respiratory distress syndrome (ARDS).

27 Dec 2024

New insights into respiratory syncytial virus and prevention strategies

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health concern. Currently, there are no effective medications for RSV, and current treatment focuses on providing supportive care and preventing its spread.

20 Dec 2024

Nanozyme breakthrough offers new hope for viral pneumonia treatment

A recent study in Nature Materials introduces an inhalable nanozyme treatment for viral pneumonia, showing promising results in reducing inflammation and viral load in various mouse models. The nanozyme, CeTA-K1tkP, demonstrates broad-spectrum effects and biocompatibility, offering a potential new approach to treating pneumonia and other inflammatory conditions.

3 Dec 2024

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients

The ASUNCTIS trial evaluated asunercept's safety and efficacy in COVID-19, showing trends toward faster recovery despite not meeting statistical significance.

18 Nov 2024

Tissue chips help translate respiratory disease research into clinical applications

Scientists are developing advanced tools to understand and treat neurological symptoms such as brain fog associated with respiratory diseases like influenza.

17 Oct 2024

Rice and Baylor receive $2.8 million to suppress inflammation and lung damage in ARDS patients

Rice University and Baylor College of Medicine have received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), for research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients.

19 Sep 2024

Columbia researchers link ferroptosis to COVID-19 lung disease

In some severe cases of COVID-19, the lungs undergo extreme damage, resulting in a range of life-threatening conditions like pneumonia, inflammation, and acute respiratory distress syndrome.

20 May 2024

Acetaminophen shows potential in preventing acute respiratory distress syndrome, organ injury in sepsis patients

A National Institutes of Health (NIH)-supported clinical trial has found that intravenous acetaminophen reduced sepsis patients' risk of having organ injury or developing acute respiratory distress syndrome, a serious condition that allows fluid to leak into the lungs.

20 May 2024

Can vitamin D3 supplementation reduce COVID-19 severity?

The effectiveness of Vitamin D3 supplementation in reducing intensive care unit admissions.

10 May 2024

Heightened risk of adverse neonatal outcomes from prenatal exposure to both cannabis and nicotine

A recent JAMA Network Open study found that combined prenatal use of nicotine and cannabis significantly increases risks for adverse perinatal outcomes, such as higher rates of hypertensive disease, preterm delivery, and elevated infant mortality compared to using neither or only one substance.

9 May 2024

Vaping poses unexpected risks to eye health, study finds

A study in the Journal of Clinical Medicine reveals that exposure to e-cigarette vapor can lead to both accidental and direct ocular injuries, including changes in tear film stability and potential ocular surface malignancies.

30 Apr 2024

Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity

Researchers identified how SARS-CoV-2 targets and manipulates specific lung cells, using innovative techniques to trace the virus's impact on the cells' gene expression, revealing insights into early COVID-19 pathogenesis.

14 Apr 2024

Heart at risk from ARDS: Inflammatory responses fuel cardiovascular complications

Research highlights the inflammatory impacts of ARDS on the heart, underscoring the role of immune responses in cardiovascular complications from viral infections, including COVID-19, and emphasizes the potential of TNF-α neutralizing therapy to mitigate these effects.

24 Mar 2024

SARS-CoV-2-associated ARDS can damage the heart without direct infection

SARS-CoV-2, the virus that causes COVID-19, can damage the heart even without directly infecting the heart tissue, a National Institutes of Health-supported study has found.

20 Mar 2024